Your browser doesn't support javascript.
loading
Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial.
Sudhan, Dhivya R; Schwarz, Luis J; Guerrero-Zotano, Angel; Formisano, Luigi; Nixon, Mellissa J; Croessmann, Sarah; González Ericsson, Paula I; Sanders, Melinda; Balko, Justin M; Avogadri-Connors, Francesca; Cutler, Richard E; Lalani, Alshad S; Bryce, Richard; Auerbach, Alan; Arteaga, Carlos L.
Affiliation
  • Sudhan DR; Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Schwarz LJ; Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Guerrero-Zotano A; Oncosalud-AUNA, Lima, Peru.
  • Formisano L; Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Nixon MJ; Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Croessmann S; Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
  • González Ericsson PI; Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Sanders M; Breast Cancer Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Balko JM; Breast Cancer Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Avogadri-Connors F; Department of Pathology, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Cutler RE; Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Lalani AS; Breast Cancer Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Bryce R; Department of Cancer Biology, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Auerbach A; Puma Biotechnology Inc., Los Angeles, California.
  • Arteaga CL; Puma Biotechnology Inc., Los Angeles, California.
Clin Cancer Res ; 25(2): 771-783, 2019 01 15.
Article in En | MEDLINE | ID: mdl-30274983
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Receptors, Estrogen / Receptor, ErbB-2 Type of study: Clinical_trials Limits: Animals / Female / Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2019 Document type: Article Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Receptors, Estrogen / Receptor, ErbB-2 Type of study: Clinical_trials Limits: Animals / Female / Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2019 Document type: Article Country of publication: Estados Unidos